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The aim of this study was to evaluate the activity of the EO and its major components of Ocimum basilicum var. Maria Bonita,
a genetically improved cultivar, against the fluconazole sensitive and resistant strains of Candida albicans and Cryptococcus
neoformans. Geraniol presented better results than the EO, with a low MIC (76 𝜇g/mL against C. neoformans and 152 𝜇g/mL
against both Candida strains). The combination of EO, linalool, or geraniol with fluconazole enhanced their antifungal activity,
especially against the resistant strain (MIC reduced to 156, 197, and 38 𝜇g/mL, resp.).The ergosterol assay showed that subinhibitory
concentrations of the substances were able to reduce the amount of sterol extracted. The substances tested were able to reduce the
capsule size which suggests they have an important mechanism of action. Transmission electron microscopy demonstrated cell
wall destruction of C. neoformans after treatment with subinhibitory concentrations. In C. albicans ultrastructure alterations such
as irregularities in the membrane, presence of vesicles, and cell wall thickening were observed.The biofilm formation was inhibited
in both C. albicans strains at MIC and twiceMIC.These results provide further support for the use ofO. basilicum EO and its major
components as a potential source of antifungal agents.
1. Introduction
Candidiasis is a fungal disease that affects a large number of
individuals. Skin or mucous membranes are the most com-
mon sites of infection, especially the mouth and vagina [1].
However, the disease may evolve from a superficial infection
to systemic infection, especially in immunocompromised
individuals [2, 3]. The most frequent etiological agent of
candidiasis is Candida albicans. This pathogen is an oppor-
tunistic fungus able to form biofilms, which are of major
clinical concern. Moreover, fungi communities structured
in extracellular polysaccharide matrices possess increased
resistance to antifungal therapy [3, 4].
C. neoformans is responsible for cryptococcosis, a disease
affecting the central nervous system and having high levels
of mortality. C. neoformans has several well-characterized
virulence factors such as capsular polysaccharide, sialic acids,
and the production of mannitol and melanin. The former
is considered the most important virulence factor of C.
neoformans and therefore the most studied. The capsule
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contributes to the microorganism virulence through mul-
tiple mechanisms, including antiphagocytic properties and
adverse effects on the host immune system [5, 6].
Despite current antifungal therapies, cryptococcal and
candidal infections show unpleasant high mortality rates
in immunocompromised individuals. A study conducted by
Park et al. [7] revealed that cryptococcal meningitis was
responsible for 624,700 deaths after 3 months of infec-
tion. A previous case-control study indicated that mortality
attributable to invasive Candida infection was about 19–24%
among hospitalized patients [8]. Factors that contribute to
this scenario include a limited antifungal arsenal, diverse side
effects, and drug resistant strains [1].
Essential oils (EOs) and plant extracts are commonly
used in traditional medicine by indigenous populations
worldwide [9, 10]. EOs are complex mixtures of volatile
(terpenes, aliphatic aldehydes, alcohols, and esters) and
nonvolatile components (hydrocarbons, fatty acids, sterols,
carotenoids, waxes, coumarins, and flavonoids) produced by
aromatic plants as secondarymetabolites [11]. Various studies
have attributed different biological activities to EOs such as
antiviral, antigiardial, antispasmodic, carminative, analgesic,
healing, expectorant, antiseptic, respiratory tract, and anti-
inflammatory activities [12–16].
Ocimum basilicum (Lamiaceae) is found in tropical and
subtropical regions of Asia, Africa, Central America, and
South America [17]. Popularly known as basil,O. basilicum is
a culinary and medicinal herb widely used in folk medicine
to combat headaches, coughs, intestinal worms, and kidney
disorders and as an antispasmodic agent [18]. The antimi-
crobial activity of basil EO has been reported to be pre-
dominantly associated with its major components, linalool
and methyl chavicol [19]. The antimicrobial activity of these
components and other monoterpenes has been reported
in the literature against various microorganisms, including
protozoans, bacteria, and fungi [20–23]. The purpose of this
study was to investigate the antifungal activity of the essential
oil and its major components (linalool and geraniol) from a
genetically improved O. basilicum cultivar (O. basilicum var.
Maria Bonita) against C. neoformans and fluconazole (FLC)
sensitive and resistant C. albicans strains.
2. Material and Methods
2.1. Chemicals. Fluconazole (FLC), resazurin, 2,3-bis(2-me-
thoxy-4-nitro-5sulfofenil)-5-[(phenylamino)carbonyl]-2H-
tetrazolium hydroxide (XTT), 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazoliumbromide (MTT), linalool (97%), and
geraniol (98%) standards were obtained from Sigma-Aldrich
(USA) and stored according to the supplier’s instructions.
All solvents used were of spectroscopic grade from Tedia
(Fairfield, OH, USA).
2.2. Plant Material and Essential Oil. Ocimum basilicum L.
var. “Maria Bonita” is a genetically improved cultivar with a
high content of linalool.O. basilicum EOwas provided by the
Federal University of Sergipe, where a voucher specimen was
deposited (register number 13162). EOwas extracted from the
leaves by hydrodistillation using a Clevenger apparatus. The
chemical composition of the EO was analyzed by a GC-MS
and previously published by Da Costa et al. [24] and linalool
was identified as the major component of the EO (75.22%),
followed by geraniol (14.66%).
2.3. Microorganisms. Cryptococcus neoformans T-444 sero-
type A was provided by Universidade Federal de Sa˜o Paulo
(UNIFESP). C. albicans FLC resistant strain was isolated
from the oral cavity of a pediatric patient infected with
HIV and C. albicans (7173 serotype B) and was kindly
provided by Hospital Evandro Chagas/FIOCRUZ/RJ. The
microorganismsweremaintained in Sabouraud dextrose agar
for 48 h at room temperature.
2.4. Macrophage Culture. Macrophage cell line RAW 264.7
was purchased from the Rio de Janeiro cell bank. Cells were
grown in Dulbecco’s Modified Eagle Medium (DMEM) sup-
plemented with 2mM L-glutamine, 50𝜇g/mL gentamicin,
and 2.5 𝜇g/mL Fungizone, plus 10% of heat-inactivated fetal
bovine serum (FBS) andmaintained at 37∘C in an atmosphere
of 5% CO
2
.
2.5. Evaluation of Inhibitory Concentrations. The minimum
inhibitory concentration (MIC) was determined using the
microdilution broth method according to CLSI M27-A [25].
First, theO. basilicum EO and linalool and geraniol standards
were serially diluted into 96-well plates in duplicates. Then
100 𝜇L of cell suspension (103 yeast/mL) was added to each
well and the plate was incubated at room temperature for
24 or 48 h. Positive controls were prepared using yeast
inoculated growth medium (untreated cells). Pure medium
was used for the negative controls. Growth inhibition was
confirmed after the addition of 30 𝜇L of resazurin solution
(5mg/100mL of phosphate buffer saline, PBS; pH 7.2) and
further incubation at 37∘C for 3 h. FLC was used as the
antimicrobial standard drug. MIC was defined as the lowest
concentration of the EO, linalool, and geraniol that com-
pletely invalidated the microorganism growth.
2.6. Synergism Assay with the Antifungal Standard Drug
FLC. The synergistic effect of the EO, linalool, and geraniol
on FLC antifungal activity was performed as previously
described by Zore et al. [23], with slight modifications. FLC
and O. basilicum EO or its major components (linalool and
geraniol) were combined at concentrations lower than their
individual MIC values into 96-well microplates. Each plate
was inoculated with 103 cells/mL and incubated at room
temperature for 24 h or 48 h, according to the requirements of
themicroorganisms.The results were based on visual growth,
which were confirmed with the addition of resazurin as
described above. Fractional inhibitory concentrations (FICs)
for each substance and in their combination with FLC were
calculated as follows:
FICindex
=
concentration that inhibits 100% of growth in combination
concentration that inhibits 100% of growth alone
.
(1)
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The FICindex was calculated by adding both FIC values.
FICindex values <0.5 and >4.0 have synergistic and antagonis-
tic interactions, respectively [26].
2.7. Determination of the Amount of Ergosterol. Sterol extrac-
tion was performed as previously reported by Arthington-
Skaggs et al. [27], with a slight modification. A single C. albi-
cans or C. neoformans colony from an overnight Sabouraud
dextrose agar plate culture was inoculated in 50mL of
Sabouraud dextrose broth containing different concentra-
tions of the EO, linalool, and geraniol (625, 395, and 38𝜇g/mL
for C. neoformans and 625, 395, and 76 𝜇g/mL for C. albicans,
resp.). C. albicans and C. neoformans cultures were incubated
at 37∘C for 18 and 24 h, respectively, with shaking. The cells
were harvested by centrifugation and washed with sterile
water.The wet weight of the cell pellet was determined.Three
milliliters of 25% alcoholic potassium hydroxide solution
(25 g of KOH and 36mL of sterile distilled water, brought to
100mL with 100% ethanol) was added and mixed by vortex
for 1min. Cell suspensions were incubated in a water bath
at 85∘C for 1 h. After the incubation period, the tubes were
cooled at room temperature. The extraction of the sterols
was carried out by the addition of 1mL of sterile distilled
water and 3mL of cyclohexane and then mixing by vortex
for 3min. The cyclohexane layer was transferred to a clean
borosilicate glass tube. Then, 200𝜇L aliquot of sterol extract
was diluted fivefold in 100% ethanol and scanned spec-
trophotometrically between 200 and 300 nm (DU 530 Life
Science UV/Visible Spectrophotometer, Beckman Coulter)
[27].
Both 24(28)-dehydroergosterol (24(28) DHE, a late sterol
pathway intermediate) and ergosterol absorb at 281.5 nm, but
only 24(28) DHE shows an absorption spectrum at 230 nm.
Ergosterol content was calculated as a percentage of the wet
weight of the cells using the following equations: % ergosterol
+ % 24(28) DHE = [(𝐴
281.5
/290) × 𝐹]/pellet weight; % 24(28)
DHE = [(𝐴
230
/518) × 𝐹]/pellet weight, and % ergosterol =
[% ergosterol + % 24(28) DHE] − %24(28) DHE, where 𝐹 is
the factor for dilution in ethanol and 290 and 518 are the 𝐸
values determined for crystalline ergosterol and 24(28) DHE,
respectively [28].
2.8. Antibiofilm Formation Activity. The effects of the O.
basilicum EO, linalool, and geraniol against C. albicans
biofilm formation were evaluated. In order to assure better
yeast adhesion, 96-well microplates were pretreated with
100 𝜇L of fetal bovine serum (FBS) for 30 minutes at 37∘C.
The microplates were washed with PBS and then 100 𝜇L of C.
albicans suspension (1 × 107 cells/mL) in YNB (yeast nitrogen
base) broth, supplemented with 2% glucose, pH 7.0, was
inoculated into the wells and incubated at 37∘C for 90min.
Nonadherent cells were removed by washing the microplates
twice with PBS, and then 100𝜇L of different concentrations
of the EO, linalool, and geraniol was added to the wells
(final concentrations at one- and twofold MIC). After 48 h
incubation at 35∘C, themediumwas removed and the biofilm
was washed with PBS [29]. The untreated biofilms were used
as positive control.
Biofilm quantification was made by the cellular reduc-
tion of salt XTT. First, 150 𝜇L of XTT-menadione solution
(12.5 𝜇g/mL of XTT + 0.17 𝜇g/mL of menadione) in PBS was
added to each well, and then the microplates were incubated
for 2 h at 35∘C in the dark. After the incubation period,
100 𝜇L from each well was transferred to another 96-well
microplate and the optical density was determined at 475 nm
(SpectraMax M5, Molecular Devices, USA) [29].
2.9. Transmission Electron Microscopy. C. neoformans, FLC
sensitive, and resistant C. albicans strains were treated with
subinhibitory concentrations of the EO (625 𝜇g/mL for all
microorganisms) and geraniol (38 𝜇g/mL for C. neoformans
and 76 𝜇g/mL for both C. albicans strains) for 48 h at 37∘C.
The yeasts were washed in PBS, pH 7.2, and fixed in a
solution of 2.5% glutaraldehyde and 4% formaldehyde in
0.1M cacodylate buffer, pH 7.2, for 1 h at room temperature.
Next, the yeasts were postfixed for 2 h in 1% osmium tetroxide
containing 1.25% potassium ferrocyanide and 5mMCaCl
2
in
cacodylate buffer, pH 7.2. The yeasts were then washed in the
same buffer, dehydrated with increasing ethanol concentra-
tions (30, 50, 70, 90, and 100% and ultradry ethanol), with the
cells remaining in each concentration for 30min, and then
embedded in Spurr resin. Ultrathin sections were stained
with uranyl acetate and lead citrate, and imageswere obtained
using a Zeiss 900 electron microscope equipped with a CCD
Camera (mega view IIImodel, Soft Image System, Germany).
The images were processed with iTEM software (Soft Image
System, Germany).
2.10. C. neoformans Capsule Size. C. neoformans was incu-
bated for 48 h at 35∘C in the presence of subinhibitory
concentrations of EO, linalool, and geraniol (625, 395, and
38 𝜇g/mL, resp.). After 48 h, an aliquotwas removed andfixed
with a formaldehyde solution (10% formaldehyde in PBS)
to measure capsule sizes. Slides were prepared for measure-
mentswith a drop of cells and a drop of India ink dye to enable
capsule visualization.The images were obtained using a Zeiss
Axioplan microscope. Measurements were performed using
ImageJ software considering the distance between the cell
wall and the outer edge of the capsule. Each cell wasmeasured
in four different regions to obtain the average capsule size.
Thirty cells were analyzed for each condition.
2.11. Cytotoxicity. Cytotoxicity was assessed via MTT reduc-
tion as previously described [30]. Several concentrations of
O. basilicum EO, linalool, and geraniol ranging from 5000 to
310 𝜇g/mL, 3156 to 197 𝜇g/mL, and 612 to 38.3 𝜇g/mL, respec-
tively, were placed in contact with the RAW cell cultures
and incubated at 37∘C for 24 h. Next, 10 𝜇L of MTT solution
was added to cell cultures and incubated for 3 h at 37∘C.
The formazan crystals formed were solubilized by adding
100 𝜇L of dimethylsulfoxide (DMSO). The absorbance was
determined at 490 nm in an automatic spectrophotometer
(ELx800TMBio-TeK Instruments, Inc.). The 50% cytotoxic
concentration (CC50) was defined as the compound concen-
tration which caused a 50% reduction in the number of viable
cells.
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Table 1: Evaluation of interaction resulting from the combination of the substances tested by determining the FICindex using the checkerboard
technique.
Strain MIC (𝜇g/mL) MIC in combination (𝜇g/mL)
EO La Gb FLCc FLC EO FIC
d
index FLC L
FIC
index FLC G
FIC
index L G
FIC
index
C. neoformans 1250 790 76 31.25 4.14 625 0.633(I)e 8.054 197
0.5077
(I) 4.14 19
0.3826
(S) 111 19
0.3905
(S)
C. albicans resistant 1250 1580 152 500 1.01 156 0.127(S)f 2.02 197
0.134
(S) 1.04 38
0.252
(S) 397 4.8
0.284
(S)
C. albicans sensitive 1250 790 152 0.975 0.259 312 0.51(I) 0.065 395
0.57
(I) 0.259 38
0.51
(I) 105 38
0.38
(S)
aL: linalool; bG: geraniol; cFLC: fluconazole; dFIC index: fractional inhibitory concentration index; eI: indifferent; fS: synergist.
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Figure 1: Effect of 625 𝜇g/mL of EO, 395 𝜇g/mL of linalool, and 38 𝜇g/mL of geraniol on the inhibition of ergosterol synthesis inC. neoformans
(a) and the effect of 625 𝜇g/mL of EO, 395 𝜇g/mL of linalool, and 76 𝜇g/mL of geraniol on the C. albicans sensitive strain (b). The results
represent the mean ± standard error of two independent experiments in triplicate.
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Figure 2: Effect of 625𝜇g/mL EO, 395 𝜇g/mL linalool, and 38 𝜇g/mL geraniol on the capsule size.
3. Results and Discussion
The results of minimum inhibitory concentrations are shown
in Table 1. The MIC values found for the EO against C. neo-
formans, C. albicans sensitive, and C. albicans resistant strain
were similar (1250 𝜇g/mL). Geraniol was the most effective
compound against all the strains tested (76 𝜇g/mL against
C. neoformans and 152𝜇g/mL against the two C. albicans
strains tested). However, different results were observed with
linalool. The MIC for linalool was 790 𝜇g/mL against C.
neoformans and C. albicans sensitive and 1580𝜇g/mL against
the C. albicans fluconazole resistant strain. Our preliminary
results with MIC corroborate with reports in the literature
that show antimicrobial properties of extracts and essential
oils of other natural products and their major components
[31–37].
These results encouraged us to evaluate the combination
of EO, linalool, and geraniol with a standard drug. Previous
works have reported that the combination of different anti-
fungal agents or the combination of natural products and
standard drugs could reduce their separateMIC values. Liu et
al. [38] showed that the combination of FLC and glabridin, an
isoflavan isolated from Glycyrrhiza glabra, reduced the MIC
values of C. neoformans, indicating a synergistic effect. Faria
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Figure 3: Effect of O. basilicum EO, geraniol, and linalool standards on the mitochondrial reducing activity (MRA) of biofilms formed by C.
albicans sensitive (a, c, e) and C. albicans fluconazole resistant (b, d, and f) treated with one- and twofold MIC concentrations. The results
represent the mean ± standard error of two independent experiments in triplicate. Values over the bars refer to the percentage of inhibition
of biofilm viability.
et al. [39] found a synergistic effect in the combination of
2,5-dihydroxybenzaldehyde and FLC against C. neoformans.
In this work, we evaluate the effect of EO and its major
components (geraniol and linalool) with the reference drug
FLC and the combination of the two major components
against C. neoformans. All the combinations tested produced
FICindex values ranging from 0.3826 to 0.6326. This showed
that all these combinations reduced the MIC values. The
synergistic effect was observed in the combination of FLC
and geraniol, reducing their MIC from 31.25 to 4.14 𝜇g/mL
and 76 to 19 𝜇g/mL, respectively, and in the combination of
linalool with geraniol, reducing their MIC values from 790 to
111 𝜇g/mL and 76 to 19 𝜇g/mL, respectively. When FLC was
combined with 197𝜇g/mL linalool and 625 𝜇g/mL EO, their
MIC values were reduced from 31.25 to 8.054 and 4.14 𝜇g/mL
in the respective combinations (Table 1). It is important to
note that, in combination, the needed concentrations of the
two major components together to completely eradicate C.
neoformans were very low. No combination of O. basilicum
EO and commercial antifungal agents against C. neoformans
was found in the literature consulted.
For the Candida albicans strains all the combinations
tested produced FICindex values ranging from 0.127 to 0.57.
Although all the combinations reduced the MIC values in at
least one of the paired substances, we did not observe any
synergistic effect in the combinations of natural components
with FLC against C. albicans sensitive. However, a synergistic
effect was observed in the combination of linalool with
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Figure 4: Transmission electronmicroscopy ofC. neoformansT444 strain treatedwith 625 𝜇g/mLof EO, 38𝜇g/mLof geraniol, and 395 𝜇g/mL
of linalool for 48 h at 37∘C. Untreated cells (control) showed good preservation of cell wall and membrane and the final of budding (a–c).
The cells treated with 625 𝜇g/mL of EO (d), 38 𝜇g/mL of geraniol, (e) and 395 𝜇g/mL of linalool (f) showed a disruption of the fungal capsule
structure.
geraniol, reducing their MIC values from 790 to 105𝜇g/mL
and 152 to 38 𝜇g/mL, respectively. Furthermore, all combi-
nations tested presented synergistic effect against C. albicans
resistant. When FLC was combined with EO 156𝜇g/mL,
its MIC value was reduced from 500 to 1.01 𝜇g/mL. The
combination of FLC with 197𝜇g/mL linalool and 38 𝜇g/mL
geraniol reduced its MIC value from 500 to 2.02 𝜇g/mL and
to 1.04 𝜇g/mL, respectively.This is a significant result because
when the high concentrations of the standard drugs are
reduced the collateral effects are also reduced. Moreover, the
combination of linalool and geraniol caused complete cellular
inhibition at reduced MICs of 4.8 𝜇g/mL and 397 𝜇g/mL for
geraniol and linalool, respectively (Table 1). These results
corroborate with previously reported results that show the
synergistic effect of geraniol and FLC against C. albicans [22].
However, when compared with our study, a higher concen-
tration of geraniol (140 𝜇g/mL) was necessary to reduce the
MIC value of FLC from 64 to 2 𝜇g/mL.
In order to investigate the mechanisms of action of EO,
linalool, and geraniol, we analyzed the inhibition of ergosterol
synthesis. Ergosterol is an important sterol presented in
the yeast cell membrane that controls membrane fluidity
and integrity, and it is an important target for some anti-
fungals [40–42]. The treatment of C. neoformans with EO
(625 𝜇g/mL), linalool (395 𝜇g/mL), and geraniol (38 𝜇g/mL)
results in an inhibition of 79, 57, and 25% of ergosterol
synthesis, respectively (Figure 1(a)). Even in subinhibitory
concentrations, the substances tested were able to reduce the
Evidence-Based Complementary and Alternative Medicine 7
500nm
(a)
200nm
(b)
500nm
(c)
200nm
(d)
500nm
(e)
200nm
(f)
Figure 5: Transmission electronmicroscopy ofC. albicans fluconazole sensitive strain treatedwith 625𝜇g/mL of EO and 76 𝜇g/mL of geraniol
for 48 h at 37∘C.The control (untreated) C. albicans sensitive strain cells showed good preservation of cell wall andmembrane (a and b). Cells
treated with 625 𝜇g/mL of EO presented cell wall thickening (c and d) and the treatment with 76 𝜇g/mL of geraniol led to the appearance of
cell membrane invaginations presenting some vesicles and the thickening of the cell wall (e and f).
ergosterol content. This is an indication that they might act
in the ergosterol biosynthesis pathway, especially the EO and
linalool.
The treatment of C. albicans sensitive with EO
(625 𝜇g/mL), linalool (395 𝜇g/mL), and geraniol (76 𝜇g/mL)
resulted in an inhibition of 63, 38, and 38% of ergosterol
synthesis, respectively. A similar effect was obtained with C.
albicans resistant (Figure 1(b)). These data corroborate with
those reported by Khan et al. In that study, the treatment
with O. sanctum essential oil and linalool was also able to
decrease ergosterol synthesis in C. albicans [43]. However,
in another study, geraniol and linalool were not effective in
reducing the ergosterol content in C. albicans, even at higher
concentrations (4mg/mL and 8mg/mL, resp.) [44].
Another mechanism of action analyzed in this study was
the ability of the studied components to reduce the capsule
size of C. neoformans. The capsule is the major virulence
factor of C. neoformans and it is an important target of study
[45]. In the sub-MIC concentrations tested, linalool showed
the highest activity in reducing the capsule size, followed by
EO, and geraniol was the least active (Figure 2).The presence
of capsules can alter the susceptibility of antimicrobial drugs;
therefore, finding natural products that reduce capsule size
is extremely important. The results here suggest that the
three substances tested can reduce the capsule size; and
therefore they might be used with other antimicrobial drugs
to reduce the concentration needed and consequently its
collateral effects. Vitale et al. tested the activity of antifungal
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Figure 6: Transmission electronmicroscopy ofC. albicans fluconazole resistant strain treatedwith 625𝜇g/mL of EO and 76 𝜇g/mL of geraniol
for 48 h at 37∘C. Control cells showed good preservation of the membrane, cell wall, and small vesicles near the membrane (a and b). Yeasts
treated with subinhibitory concentrations of the essential oil and geraniol showed cell wall thickening and irregularities in the membrane
(c and d). Cells treated with subinhibitory concentration of geraniol presented cell wall thickening and irregularities in cell membrane,
suggesting budding failure (e and f).
agents against strains of C. neoformans with different capsule
sizes. They showed that the presence of capsules affects the
susceptibility of the yeast to the antimicrobial tested [46].
The activity of the EO, linalool, and geraniol against C.
albicans biofilm formation was evaluated and the EO was the
most effective. At 2x, its MIC value geraniol appears to be
more effective against C. albicans sensitive biofilm formation
than C. albicans resistant. EO showed the highest biofilm
inhibitory activity against both C. albicans strains at MIC
followed by linalool and geraniol, respectively (Figure 3).
Alviano et al. demonstrated that the essential oil of Croton
cajucara and purified linalool were effective against artificial
biofilms of C. albicans [47]. A previous study showed that
the essential oil of Boesenbergia pandurata, with a high
content of geraniol (56.68%) and 2.36% of linalool, was
able to interfere in the initial phases of Candida biofilm
formation [48]. Another study showed a strong antimicrobial
activity of the essential oil of O. americanum L. against
the planktonic form of C. albicans but a less pronounced
effect on these microorganisms in biofilms [49]. The biofilm
inhibitory activities of linalool and geraniol obtained in the
present study are consistent with those described by Dalleau
et al., who demonstrated that geraniol was the most effective
substance against C. albicans biofilm [50].
In order to observe the ultrastructural changes in the
C. neoformans strain after treatment with EO, linalool, and
geraniol, the treated and untreated cells, grown for 48 h at
37∘C, were processed for transmission electron microscopy.
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Figure 7: Transmission electron microscopy of C. albicans fluconazole resistant strain treated with FLC alone (1𝜇g/mL) and combined
with geraniol (38 𝜇g/mL) and EO (156𝜇g/mL); the latter two trails with FLC exhibited synergistic activity. The treatment with 1𝜇g/mL of
FLC showed cells with irregularity in their membranes and formation of small vesicles in the proximity (a-b). In the treatment with the
combination of essential oil 156𝜇g/mL and FLC 1 𝜇g/mL, the cells demonstrated a very thick cell wall and membrane invaginations (c-d).
Cells treated with the combination of geraniol 38 𝜇g/mL and FLC 1 𝜇g/mL showed extensive irregularities in the membrane and formation
of membrane vesicles in the cytoplasm (e-f).
Untreated cells (control) showed good preservation of cell
walls and membrane and the final of budding (Figures 4(a)–
4(c)). The cells treated with 625𝜇g/mL of EO (Figure 4(d)),
38 𝜇g/mL of geraniol (Figure 4(e)), and 395 𝜇g/mL of linalool
(Figure 4(f)) showed a disruption of the fungal capsule
structure.
The control (untreated) C. albicans sensitive strain cells
showed good preservation of their cell walls and membranes
(Figures 5(a) and 5(b)). Cells treated with 625𝜇g/mL of EO
presented cell wall thickening (Figures 5(c) and 5(d)) and the
treatment with 76𝜇g/mL of geraniol led to the appearance
of cell membrane invaginations presenting some vesicles and
the thickening of the cell walls (Figures 5(e) and 5(f)). The
control cells ofC. albicans fluconazole resistant strain showed
good preservation of the membrane, cell wall, and small
vesicles near themembrane (Figures 6(a) and 6(b)). However,
yeasts treated with subinhibitory concentrations of EO and
geraniol showed cell wall thickening and irregularities in
the membrane (Figures 6(c) and 6(d)). Cells treated with a
subinhibitory concentration of geraniol presented cell wall
thickening and irregularities in the cell membrane, suggest-
ing budding failure (Figures 6(e) and 6(f)).
In Figure 7, the transmission electron microscopy of
C. albicans fluconazole resistant strain treated with FLC
alone and in combination with geraniol and EO exhibited
a synergistic activity with FLC. FLC treated with 1𝜇g/mL
cells has irregularity in themembrane and formation of small
vesicles in the proximity (Figures 7(a) and 7(b)). Treated
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with the combination of essential oil 156 𝜇g/mL and FLU
1 𝜇g/mL cells presented a very thick cell wall and membrane
invaginations (Figures 7(c) and 7(d)). Cells treated with
the combination of geraniol 38 𝜇g/mL and FLU 1 𝜇g/mL
showed large irregularities in themembrane and formation of
membrane vesicles in the cytoplasm (Figures 7(e) and 7(f)).
The cytotoxic activities of essential oil, geraniol, and
linalool were analyzed on a RAW cell line and showed CC
50
at a concentration of 380 𝜇g/mL for geraniol and less than
310 𝜇g/mL and 197 𝜇g/mL (the lowest concentrations evalu-
ated) for essential oil and linalool, respectively. According to
this, theMIC values found for geraniol weremuch lower than
the CC
50
. Using the checkerboard,MIC values of linalool and
EO were reduced to 105 and 156 𝜇g/mL, respectively, in some
combinations, which can minimize the cytotoxic activity of
these components.
4. Conclusions
In this study we showed that geraniol displayed the high-
est activity against C. neoformans and the strains of C.
albicans tested and the lowest cytotoxicity, when compared
with linalool and the EO The ergosterol inhibition and
the synergism showed the potential activity of this natural
product and that its combination with standard drugs can
be useful against the microorganisms tested. The anticryp-
tococcal activity described here encourages the search for
more effective substances of vegetal origin for the treatment
of cryptococcosis.
Besides the antifungal activity described here the results
support the use ofO. basilicum essential oil as a folkmedicine
and open perspectives to find more effective substances from
vegetal origin for the treatment of fungal diseases.
Appendix
See Table 1.
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